Accord Healthcare Inc, a US-based generic pharmaceutical company, announced on Wednesday that it has added Dehydrated Alcohol Injection to its line of cardiovascular drugs.
Accord's product is AB-rated to BPI Labs' Ablysinol and is offered in 99% 5mL vials.
Dehydrated Alcohol is approved by the FDA and is indicated to induce controlled cardiac septal infarction to improve exercise capacity in adults with symptomatic hypertrophic obstructive cardiomyopathy who are not candidates for surgical myectomy.
"The launch of Accord Healthcare's Dehydrated Alcohol Vials represents a meaningful advancement in offering a more convenient alternative to the traditional ampule market," said Chrys Kokino, Accord Healthcare US president.
Biovica secures European patent for biomarker use in immuno-oncology
Valneva signs exclusive German vaccine distribution deal with CSL Seqirus
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Alvotech reports positive topline results for Xolair biosimilar study
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Scancell expands Phase 2 SCOPE trial with new intradermal dosing arm for iSCIB1+
Telix Pharmaceuticals delivers first commercial doses from Belgian manufacturing hub
Innovent presents mazdutide Phase 3 clinical study results at ADA 85th Scientific Sessions
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Aiforia Technologies launches CE-IVD marked AI solution for breast cancer diagnostics
Stockholders approve proposed merger of TuHURA Biosciences and Kineta